# Childhood Obesity: Prevention and Management

## Overview

Childhood obesity is a major public health crisis, with a prevalence of approximately 20% among US children aged 2-19 years based on NHANES 2017-2020 data. It disproportionately affects Hispanic, non-Hispanic Black, and American Indian/Alaska Native children. The condition is associated with significant cardiometabolic, psychosocial, and orthopedic comorbidities. Childhood obesity tracks strongly into adulthood, with 80% of obese adolescents becoming obese adults. The AAP 2023 Clinical Practice Guideline represents a paradigm shift toward early, intensive, and comprehensive treatment including pharmacotherapy and surgery.

## Classification

### BMI-Based Categories (Age 2-20 Years)

| Category | BMI Percentile (Ages 2-20) | Notes |
|----------|---------------------------|-------|
| Underweight | <5th percentile | Evaluate for nutritional or medical cause |
| Healthy weight | 5th-84th percentile | Goal range |
| Overweight | 85th-94th percentile | Screen for comorbidities |
| Obesity (Class I) | ≥95th percentile | IHBLT recommended |
| Severe obesity (Class II) | ≥120% of 95th percentile or BMI ≥35 | Pharmacotherapy eligible (age ≥12) |
| Class III | ≥140% of 95th percentile or BMI ≥40 | Bariatric surgery eligible |

Children are classified as underweight (BMI below 5th percentile), healthy weight (5th-84th percentile), overweight (85th-94th percentile), obesity or Class I (BMI at or above the 95th percentile), severe obesity or Class II (BMI at or above 120% of the 95th percentile or BMI 35 kg/m2 or greater), and Class III obesity (BMI at or above 140% of the 95th percentile or BMI 40 kg/m2 or greater).

### Children Under 2 Years

BMI is not used for children under 2; weight-for-length charts are appropriate. Weight-for-length above the 97.7th percentile indicates excess weight, and rapid weight gain crossing upward percentiles is a risk factor for later obesity.

### Limitations of BMI

BMI does not distinguish fat mass from lean mass, may underestimate adiposity in children with low muscle mass, and shows ethnic variation in body composition at equivalent values. Despite these limitations, BMI remains the recommended screening tool.

## Pathophysiology and Risk Factors

### Energy Balance

While obesity is fundamentally driven by caloric intake exceeding energy expenditure, it is far more complex than simple "calories in versus calories out." Genetic, epigenetic, hormonal, neurobiological, environmental, and psychosocial factors all contribute to its development and persistence.

### Genetic Factors

The heritability of BMI ranges from 40-70%. Rare monogenic causes include leptin deficiency, MC4R mutations (the most common monogenic cause, accounting for 2-5% of severe early-onset obesity), POMC deficiency, Bardet-Biedl syndrome, and Prader-Willi syndrome. Polygenic susceptibility involves more than 900 identified genetic loci, each with small individual effects.

### Environmental and Behavioral Factors

Contributing factors include sugar-sweetened beverage consumption, large portion sizes, frequent fast food consumption, reduced physical activity, increased sedentary screen time, poor sleep quality and duration, food deserts with limited access to healthy options, marketing of unhealthy foods to children, and adverse childhood experiences with toxic stress.

### Endocrine Causes (Rare)

Hypothyroidism, Cushing syndrome, and growth hormone deficiency are uncommon but important to recognize. The critical clinical clue is short stature accompanying obesity, because simple exogenous obesity is associated with tall stature and advanced bone age.

<image>Diagram illustrating the multifactorial etiology of childhood obesity showing interacting layers of genetic predisposition, hormonal regulation (leptin, ghrelin, insulin), behavioral factors (diet, activity, sleep, screen time), and environmental/social determinants (food access, neighborhood safety, socioeconomic status)</image>

## Comorbidity Screening

### Metabolic

Type 2 diabetes screening (fasting glucose, HbA1c, or OGTT) should begin at age 10 or puberty onset if BMI is at or above the 85th percentile with additional risk factors. Fasting lipid panel screening begins at age 10 universally and earlier in obese children. ALT screening for NAFLD/MASLD starts at age 9-11 in obese children; elevation above twice the upper limit of normal warrants ultrasound and hepatology referral.

### Cardiovascular

Blood pressure should be measured at every visit from age 3 using the 2017 AAP normative tables referenced to age, sex, and height percentile.

### Musculoskeletal

Slipped capital femoral epiphysis (SCFE) presents with hip or knee pain and a limp in obese adolescents. Blount disease (tibia vara), flat feet, and back pain are additional musculoskeletal complications.

### Psychosocial

Depression and anxiety screening using PHQ-A and GAD-7 is important. Bullying, low self-esteem, and body image disturbance are common. Eating disorders including binge eating disorder and bulimia can coexist with obesity. Weight stigma and bias within healthcare settings must be recognized and addressed.

### Other

Obstructive sleep apnea should be screened with sleep history and polysomnography when symptoms are present. Polycystic ovary syndrome in adolescent females manifests with irregular menses, hirsutism, and acne. Pseudotumor cerebri (idiopathic intracranial hypertension) presents with headache and papilledema.

## Management: AAP 2023 Guidelines

### Key Principles

The 2023 guidelines emphasize treating early rather than watching and waiting, as obesity in children rarely resolves without intervention. Intensive health behavior and lifestyle treatment (IHBLT) is first-line for all children with obesity, involving more than 26 hours of contact over 3-12 months. Motivational interviewing is the core communication approach. Treatment must be family-based, targeting the whole family rather than singling out the child. Non-stigmatizing, person-first language ("child with obesity" rather than "obese child") is essential.

### Lifestyle Interventions (5-2-1-0 Framework)

The 5-2-1-0 framework provides a practical structure: 5 or more servings of fruits and vegetables daily, 2 hours or less of recreational screen time, 1 hour or more of physical activity daily, and 0 sugar-sweetened beverages. Additional targets include adequate sleep, family meals, portion awareness, and limiting fast food.

### Pharmacotherapy

| Medication | FDA Age Approval | Mechanism | BMI Reduction | Key Considerations |
|-----------|-----------------|-----------|---------------|-------------------|
| Semaglutide (Wegovy) | ≥12 years | GLP-1 RA | ~16% (STEP TEENS) | Most effective; weight regain on discontinuation |
| Liraglutide (Saxenda) | ≥12 years | GLP-1 RA | ~4-5% | Daily injection; GI side effects |
| Orlistat | ≥12 years | Lipase inhibitor | Modest | GI side effects limit use |
| Phentermine | ≥16 years | Sympathomimetic | Variable | Short-term use only |
| Metformin | Off-label | Insulin sensitizer | ~1-2 kg | Useful in insulin-resistant patients |
| Setmelanotide | Varies | MC4R agonist | Significant | Only for POMC, PCSK1, LEPR deficiency |

Pharmacotherapy is indicated for children 12 years and older with obesity who have not responded to lifestyle modification alone. GLP-1 receptor agonists represent the most effective medications. Semaglutide (Wegovy) is FDA-approved for age 12 and older and showed 16.1% BMI reduction at 68 weeks in the STEP TEENS trial. Liraglutide (Saxenda) is FDA-approved for age 12 and older with more modest BMI reduction of approximately 4-5%. Side effects include nausea, vomiting, diarrhea, gallstones, and rarely pancreatitis. Weight regain is expected upon discontinuation, requiring ongoing treatment for maintenance.

Additional options include orlistat (FDA-approved at age 12 and older, a lipase inhibitor with modest efficacy limited by GI side effects), phentermine (FDA-approved at 16 and older for short-term use with limited pediatric data), metformin (used off-label with modest effect of approximately 1-2 kg BMI reduction, potentially helpful in insulin-resistant adolescents), and setmelanotide (FDA-approved for rare monogenic obesity due to POMC, PCSK1, or LEPR deficiency).

### Bariatric Surgery

Bariatric surgery is indicated for adolescents with Class II obesity (BMI 35 or greater) with comorbidities or Class III obesity (BMI 40 or greater). Vertical sleeve gastrectomy is the most common procedure in adolescents, with Roux-en-Y gastric bypass as an alternative. The Teen-LABS study demonstrated significant and sustained weight loss with resolution of comorbidities (95% type 2 diabetes remission, 74% hypertension resolution). Micronutrient deficiencies require lifelong monitoring and supplementation. Surgery should be performed at centers with multidisciplinary pediatric expertise and is not appropriate before Tanner stage 4 or near-final height.

<image>Stepped management approach for pediatric obesity showing progression from prevention and lifestyle counseling for all children, to intensive health behavior and lifestyle treatment (IHBLT) for children with overweight/obesity, to pharmacotherapy for adolescents >= 12 years with obesity, to bariatric surgery for adolescents with severe obesity and comorbidities</image>

## Prevention

Prevention strategies include breastfeeding promotion (which confers a modest protective effect), appropriate introduction of complementary foods at 4-6 months, limiting sugar-sweetened beverages from early life, promoting active play while limiting screen time, family-based lifestyle modeling, and policy-level interventions including school nutrition standards, food labeling, and marketing regulation. The food insecurity paradox must be addressed: food insecurity and obesity frequently coexist in low-income families.

## Clinical Pearls

Obesity in a short child demands endocrine evaluation because simple exogenous obesity causes tall stature with advanced bone age. Depression should always be screened for in children with obesity, as the psychosocial burden may be the most impactful comorbidity. The 2023 AAP guidelines represent a paradigm shift: early, intensive treatment including pharmacotherapy is now recommended, and clinicians should not adopt a passive "wait for them to outgrow it" approach. GLP-1 agonists produce meaningful weight loss in adolescents, but weight regain occurs upon discontinuation, raising important long-term treatment implications. Person-first language should be used consistently, and children should be weighed with sensitivity and privacy. Weight bias in healthcare is real and harmful, requiring ongoing self-reflection on implicit biases.

## Key Controversy: GLP-1 Receptor Agonists in Pediatric Obesity

Semaglutide showed impressive efficacy in STEP TEENS with 16% BMI reduction, but several concerns persist. Long-term safety data in growing children are limited to less than 5 years of follow-up. Weight regain upon discontinuation suggests indefinite treatment may be necessary. Cost (approximately $1,300 per month) and insurance coverage barriers create significant equity concerns. Potential effects on bone density, growth, and pubertal development remain unknown. Ethical questions arise about medicalizing a condition with strong social and environmental drivers. The counterpoint holds that untreated severe obesity carries established lifelong morbidity, and waiting for "perfect" long-term data while children suffer is also ethically problematic.

## References
- Hampl SE, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023;151(2):e2022060640.
- Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med. 2022;387:2245-2257.
- Inge TH, et al. Five-Year Outcomes of Gastric Bypass in Adolescents (Teen-LABS). N Engl J Med. 2019;380:1570-1579.
- Skinner AC, et al. Prevalence of Obesity and Severe Obesity in US Children, 1999-2016. Pediatrics. 2018;141(3):e20173459.
- Styne DM, et al. Pediatric Obesity: Assessment, Treatment, and Prevention. J Clin Endocrinol Metab. 2017;102(3):709-757.
- Kumar S, Kelly AS. Review of Childhood Obesity. Mayo Clin Proc. 2017;92(2):251-265.